CA2389348A1 - Utilisation d'un inhibiteur de la phosphotyrosylphosphatase dans le traitement de patients immunodeprimes - Google Patents

Utilisation d'un inhibiteur de la phosphotyrosylphosphatase dans le traitement de patients immunodeprimes Download PDF

Info

Publication number
CA2389348A1
CA2389348A1 CA002389348A CA2389348A CA2389348A1 CA 2389348 A1 CA2389348 A1 CA 2389348A1 CA 002389348 A CA002389348 A CA 002389348A CA 2389348 A CA2389348 A CA 2389348A CA 2389348 A1 CA2389348 A1 CA 2389348A1
Authority
CA
Canada
Prior art keywords
bpv
compound
nfat
cells
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002389348A
Other languages
English (en)
Inventor
Michel J. Tremblay
Benoit Barbeau
Jean-Francois Fortin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virocell Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2389348A1 publication Critical patent/CA2389348A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé de restauration des fonctions immunes et de la réponse globale immune, ce procédé consistant à administrer un composé bis-peroxovanadium (bpV) faisant partie d'une famille de puissants inhibiteurs de la phosphotyrosylphosphatase. On peut utiliser ce procédé pour traiter des individus présentant des pathologies d'ordre immunitaire ou dans le traitement de patients soufrant d'infections provoquées par des virus détruisant la réponse immune naturelle, tels que le virus du syndrome immunodéficitaire acquis. Ce composé bpV peut s'utiliser en combinaison avec divers immunomodulateurs et/ou des agents antiviraux. L'invention concerne également l'utilisation d'un tel composé bpV, dans la restauration des fonctions immunes et de la réponse immune globale, chez un patient nécessitant un tel traitement.
CA002389348A 1999-10-26 2000-10-23 Utilisation d'un inhibiteur de la phosphotyrosylphosphatase dans le traitement de patients immunodeprimes Abandoned CA2389348A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16135499P 1999-10-26 1999-10-26
US60/161,354 1999-10-26
PCT/CA2000/001258 WO2001030325A2 (fr) 1999-10-26 2000-10-23 Utilisation d'un inhibiteur de la phosphotyrosylphosphatase dans le traitement de patients immunodeprimes

Publications (1)

Publication Number Publication Date
CA2389348A1 true CA2389348A1 (fr) 2001-05-03

Family

ID=22580857

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002389348A Abandoned CA2389348A1 (fr) 1999-10-26 2000-10-23 Utilisation d'un inhibiteur de la phosphotyrosylphosphatase dans le traitement de patients immunodeprimes

Country Status (4)

Country Link
EP (1) EP1225891A2 (fr)
AU (1) AU1014101A (fr)
CA (1) CA2389348A1 (fr)
WO (1) WO2001030325A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009677A2 (fr) * 2000-08-02 2002-02-07 Virocell Inc. Procede servant a traiter des maladies infectieuses et/ou a augmenter l'efficacite antimicrobienne de medicaments
US7425537B2 (en) 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
EP1383792A2 (fr) 2000-08-22 2004-01-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Inhibiteurs de liaison au domaine sh2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000236A1 (fr) * 1986-07-03 1988-01-14 Tompkins Wayne A F Procedes et materiaux d'immunomodulation au vanadium
DE4336642C2 (de) * 1993-10-22 1995-08-10 Deutsches Rheuma Forschungszen Verwendung von Vanadiumverbindungen mit antiviraler Wirkung
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
CA2280249A1 (fr) * 1999-08-12 2001-02-12 Universite Laval Composes de vanadium utilises comme facteurs anti-angiogeniques et comme inhibiteurs de production d'endotheline

Also Published As

Publication number Publication date
WO2001030325A2 (fr) 2001-05-03
EP1225891A2 (fr) 2002-07-31
AU1014101A (en) 2001-05-08
WO2001030325A3 (fr) 2002-01-24

Similar Documents

Publication Publication Date Title
Menk et al. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses
You et al. Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor
Fallarino et al. CTLA-4–Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice
Vennekamp et al. Kv1. 3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators
Xi et al. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation
Cho et al. Unique features of naive CD8+ T cell activation by IL-2
Berger et al. Calcium requirements for increased complement receptor expression during neutrophil activation.
CN113318110B (zh) 一种csf-1r激酶抑制剂的用途
WO2013107413A1 (fr) Utilisation d'un facteur associé à une voie de phosphorylation dans la régulation de la fonction des lymphocytes t régulateurs
Scharff et al. Effect of thapsigargin on cytoplasmic Ca2+ and proliferation of human lymphocytes in relations to AIDS
Xiao et al. Synthesis and biological analysis of a new curcumin analogue for enhanced anti-tumor activity in HepG 2 cells
Xavier et al. Human immunodeficiency virus type 1 Tat protein induces an intracellular calcium increase in human monocytes that requires DHP receptors: involvement in TNF-alpha production
EP0670723B1 (fr) Utilisation de thioureylenes et de thiabendazole dans les maladies auto-immunes et inflammatoires de la peau
Fortin et al. Regulation of nuclear factor of activated T cells by phosphotyrosyl-specific phosphatase activity: a positive effect on HIV-1 long terminal repeat–driven transcription and a possible implication of SHP-1
EP4188357A1 (fr) Compositions pour le traitement d'un trouble hyperprolifératif avec un inhibiteur de la synthèse du gsh et une composition anticancéreuse
CA2389348A1 (fr) Utilisation d'un inhibiteur de la phosphotyrosylphosphatase dans le traitement de patients immunodeprimes
KR19990044834A (ko) 네가티브인자작용 억제제
Emel’yanova et al. Effects of release-active antibodies to CD4 receptor on the level of lck-kinase in cultured mononuclear cells from human peripheral blood
CN109475549B (zh) 药物组合物及其治疗自身免疫疾病的用途
KR20000053216A (ko) 펩티드 면역 요법 치료제
KR102352715B1 (ko) Il-21을 이용한 항원 특이적 cd8+ t 세포의 증식 촉진 또는 대량 배양 방법
JP3699112B2 (ja) 治療用化合物
WO2020243359A1 (fr) Composés destinés à être utilisés en immunothérapie anticancéreuse
Zhang et al. Casitas B-lineage lymphoma b inhibits antigen recognition and slows cell cycle progression at late times during CD4+ T cell clonal expansion
US20200171056A1 (en) Sulfonylurea compounds in the treatment of disease associated with uv-induced damage

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued